Estrogen Receptor-Positive Breast Cancer Pipeline Market Size, Share, Competitive Landscape and Trend Analysis Report by Phase, by Route of Administration, by Target and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Estrogen receptor positive (ER +) breast cancer is the most common type of breast cancer diagnosed. It refers to cancer cells that have estrogen-binding receptors on their surface. Breast cancer is said to have a positive estrogen receptor (ER +). Breast cancer is a syndrome that affects the breast tissues. Breast cells grow out of control, forming bumps that can be felt or seen on x-rays. Selective estrogen receptor modulators such as tamoxifen is prescribed to reduce risk of endometrial cancer. Moreover, surgery such as mastectomy, medications such asletrozole, radiation, and chemotherapy are used in treatment of estrogen receptor positive breast cancer.

COVID-19 Impact Analysis             

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the estrogen receptor positive breast cancer pipeline market.

Top Impacting Factors

• Increase in cases of genetic mutation disorder, rise in prevalence of breast cancer, surge in demand for minimally invasive cancer treatments, adoption of western lifestyle, rise in consumption of tobacco, and increase in awareness regarding treatment & diagnosis of cancer are the factors that drive the growth of market.
• In addition, surge in unhealthy & sedentary lifestyle in developing countries, government initiative to build advance diagnosis centers, R & D activities to improve efficacy of breast cancer treatment therapies, launch of novel drug therapies, and emerging modern technology in developing countries are some factors that drive the growth of market.
• However, high cost of breast cancer treatment hinder the growth of market.
• Contrarily, increase in support by government to spread awareness campaign regarding breast cancer treatment & diagnosis is expected to offer lucrative opportunities in market.

Market Trends

New Product Launches to Flourish the Market

In 2020, Eisai Co. Ltd. announced launch of series of products, LENVIMA, HALAVEN, and H3B-6545. This therapeutic products help in treatment of ER positive breast cancer and HER2 negative breast cancer.

In 2019, Mylan announced launch of its generic version of Faslodex injection in U.S. This product is used in treatment of hormone receptor positive such as estrogen receptor positive breast cancer.

Key Benefits of the Report

• This study presents the analytical depiction of estrogen receptor positive breast cancer pipeline market industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the market share.
• The current market is quantitatively analyzed to highlight the market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed market analysis depending on competitive intensity and how the competition will take shape in coming years.

Questions Answered in the Estrogen Receptor Positive Breast Cancer Pipeline Market Report

• Which are the leading players active in the estrogen receptor positive breast cancer pipeline market?
• What are the current trends that will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities of the market?
• What future projections would help in taking further strategic steps?
• What is "estrogen receptor positive breast cancer pipeline "?
• What is "estrogen receptor positive breast cancer pipeline" market prediction in the future?
• Who are the leading global players in the "estrogen receptor positive breast cancer pipeline" market?
• What are the current trends and predicted trends?
• What are the key benefits of the "estrogen receptor positive breast cancer pipeline" market report?

  Estrogen Receptor-Positive Breast Cancer Pipeline Market Report Highlights

Aspects	Details
By Phase	Pre-Clinical Phase 1 Phase 2 Phase 3
By Route of Administration	Oral Intravenous Subcutaneous
By Target	Phosphatidylinositol-3-Kinase Cyclin-Dependent Kinase Histone Deacetylase Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
By End User	Hospitals Ambulatory Surgical Centers Others
Key Market Players	Mylan Pharmaceuticals Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Apotex Corp., AstraZeneca, Alvogen., Teva Pharmaceuticals USA, Inc., Genentech, Inc., Breckenridge Pharmaceutical, Inc.